Biosimilars – Commercial Best Practices In The Age Of Sustainability
The commercial landscape for biosimilars is constantly evolving. More emphasis is now being placed on sustainability than winning at all costs and any price. And with this comes a need for biosimilar companies to adopt commercial strategies that are flexible, agile and future-focused.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.